| 1.88 0 (0%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.64 | 1-year : | 3.02 |
| Resists | First : | 2.26 | Second : | 2.58 |
| Pivot price | 2  |
|||
| Supports | First : | 1.74 | Second : | 1.44 |
| MAs | MA(5) : | 1.86 |
MA(20) : | 2.03 |
| MA(100) : | 1.99 |
MA(250) : | 2.31 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 22.3 |
D(3) : | 19.9 |
| RSI | RSI(14): 41.7 | |||
| 52-week | High : | 3.37 | Low : | 1.5 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ERAS ] has closed above bottom band by 31.7%. Bollinger Bands are 29.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.89 - 1.9 | 1.9 - 1.91 |
| Low: | 1.79 - 1.8 | 1.8 - 1.81 |
| Close: | 1.86 - 1.88 | 1.88 - 1.89 |
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.
Tue, 23 Apr 2024
Erasca (ERAS) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
Mon, 22 Apr 2024
Trade Alert: The Co-Founder Of Erasca, Inc. (NASDAQ:ERAS), Jonathan Lim, Has Just Spent US$284k Buying A Few ... - Yahoo New Zealand News
Tue, 16 Apr 2024
Institutional owners may consider drastic measures as Erasca, Inc.'s (NASDAQ:ERAS) recent US$36m drop adds to ... - Simply Wall St
Mon, 01 Apr 2024
Erasca, Inc. (NASDAQ:ERAS) Q4 2023 Earnings Call Transcript - Yahoo Finance
Mon, 01 Apr 2024
Goldman Sachs raises Erasca stock target on study plans - Investing.com
Fri, 29 Mar 2024
Erasca, Inc. (ERAS) R&D Update Call and Q4 2023 Earnings Call Transcript - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 151 (M) |
| Shares Float | 86 (M) |
| Held by Insiders | 20.3 (%) |
| Held by Institutions | 47.5 (%) |
| Shares Short | 8,870 (K) |
| Shares Short P.Month | 9,900 (K) |
| EPS | -0.83 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.09 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -19.5 % |
| Return on Equity (ttm) | -34.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.91 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -101 (M) |
| Levered Free Cash Flow | -105 (M) |
| PE Ratio | -2.27 |
| PEG Ratio | 0.1 |
| Price to Book value | 0.89 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.82 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|